340B And US Drug Pricing: Trump’s First Target Is One That Lasts
The US government program that allows safety net providers to purchase drugs at deep discounts is probably not what most American voters have in mind when they say drug pricing is a top issue. But the 340B program has been a rare area of consistent focus – and actual sustained change – in the Trump Administration.
You may also be interested in...
340B Hospitals Charging Private Insurers Nearly Four Times Acquisition Costs On Cancer Drugs – Study
New report makes a case for further scrutiny of the 340B program's contributions to high drug costs, although manufacturers remain the main target of legislative and regulatory reform proposals.
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.
Medicare Part B payment loopholes also targeted in law, and Medicare Part D plans will need to offer real-time benefit tools for prescriber-patient decision making.